AI-Crafted Broad-Spectrum DNA Vaccine Enters First Human Trial
TL;DR
Cambridge researchers used AI to design a DNA vaccine targeting conserved features across the sarbecovirus family (including SARS and related bat viruses) and tested it in humans for the first time. The trial found the vaccine to be safe and capable of inducing antibodies that recognize diverse sarbecoviruses, but the immune response was modest and durability/protection in the real world remain uncertain, necessitating larger trials. If successful, such broad-spectrum, needle-free vaccines could enhance pandemic preparedness and distribution, especially in lower-income regions.
- World's First AI‑Designed Vaccine Tested in Humans For The First Time ScienceAlert
- New ‘universal vaccine’ technology could protect us from future virus outbreaks University of Cambridge
- World’s first AI-designed vaccine explained The Conversation
- New AI-Designed Universal Vaccine — What It Could Mean for Future Pandemics Before They Begin Discover Magazine
- 'World-first' vaccine designed by artificial intelligence BBC
Want the full story? Read the original reporting
Read on ScienceAlert